Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ketsia Celestin

Family Medicine Cocoa, FL Medical Doctor

NPI 1235429564 CMS profile 1305632

5005 Port St John Pkwy, Cocoa, FL 32927

Open in the dashboard

General payments

$1,055

60 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ketsia Celestin of Cocoa, FL is reported in the CMS Open Payments database as having received $1,055 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $58 3
2024 General $28 1
2023 General $140 7
2022 General $205 12
2021 General $329 18
2020 General $95 5
2019 General $201 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ketsia Celestin
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Ketsia Celestin were reported at $58. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Ketsia Celestin Family Medicine median Middle half National median
2019 $201 $150 $41–$543 $163
2020 $95 $120 $32–$415 $114
2021 $329 $137 $35–$551 $132
2022 $205 $137 $37–$512 $149
2023 $140 $149 $42–$545 $160
2024 $28 $156 $44–$560 $164
2025 $58 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $213 12 payments
  2. Lilly USA, LLC $128 7 payments
  3. Exact Sciences Corporation $104 5 payments
  4. AstraZeneca Pharmaceuticals LP $92 6 payments
  5. Novo Nordisk Inc $81 6 payments
  6. Pfizer Inc. $54 3 payments
  7. Amgen Inc. $50 3 payments
  8. Merck Sharp & Dohme Corporation $48 3 payments
  9. GlaxoSmithKline, LLC. $46 2 payments
  10. Teva Pharmaceuticals USA, Inc. $44 1 payment
  11. Other $196 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,055 60 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $109 5 payments
  2. Cologuard Collection Kit $104 5 payments
  3. Ozempic $81 6 payments
  4. TRULICITY $77 4 payments
  5. QULIPTA $66 4 payments
  6. EVENITY $50 3 payments
  7. Prolia $50 3 payments
  8. STEGLATRO $48 3 payments
  9. JANUVIA $48 3 payments
  10. SHINGRIX $46 2 payments
  11. Other $698 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 80 drugs

Part D claims

3,055

Median for Family Practice: 1,826

Drug cost

$204,421

Median for Family Practice: $120,094

Branded share of claims

21.3%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 75 $36,486
Qtern Dapagliflozin/Saxagliptin Hcl Brand 40 $26,247
Bydureon Bcise Exenatide Microspheres Brand 31 $16,939
Ozempic Semaglutide Brand 14 $12,524
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 19 $12,178
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 18 $10,604
Eliquis Apixaban Brand 17 $6,731
Rosuvastatin Calcium Generic 133 $6,525
Atorvastatin Calcium Generic 147 $5,162
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 23 $4,966

The 10 drugs with the highest cost, of 80 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record